News und Analysen

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen.

Three Fool.com contributors have done just that. Here's

Inflation is arguably the top economic story of the last couple of years. Indeed, consumer purchasing power is down 16% since the beginning of 2020. That means $1,500 would only buy $1,260 worth of

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

Dividend stocks can be incredible investments. They've historically outperformed the market over the long term. The best returns have come from companies that routinely increase their dividends.

High-yielding dividend stocks can make for great investments because they allow you to earn a lot more in dividends than you would with the average stock.

Today, the average dividend yield for an

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

Shares of Coherus BioSciences (NASDAQ: CHRS) are up 19.7% as of 3:20 p.m. ET Thursday after the U.S. Food and Drug Administration (FDA) approved Udenyca OnBody, the company's on-body injection

Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on

You might call it a "Pfizzle."

In late 2021, Pfizer (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.

It followed

You might call it a "Pfizzle."

In late 2021, Pfizer (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.

It followed

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.

When it was clear a few years ago that

Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport